- Home
- ALL vs TAK Comparison
ALL vs TAK Comparison
Compare ALL & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALL | TAK |
|---|---|---|
| Founded | 1931 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.0B | 43.3B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALL | TAK |
|---|---|---|
| Price | $202.78 | $14.20 |
| Analyst Decision | Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $223.85 | N/A |
| AVG Volume (30 Days) | 1.5M | ★ 2.9M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.98% | 1.95% |
| EPS Growth | ★ 99.54 | N/A |
| EPS | ★ 30.82 | 0.14 |
| Revenue | ★ $66,846,000,000.00 | $29,846,840,032.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.09 | $0.59 |
| P/E Ratio | ★ $6.56 | $101.77 |
| Revenue Growth | ★ 7.07 | N/A |
| 52 Week Low | $176.00 | $12.80 |
| 52 Week High | $215.89 | $15.69 |
Technical Indicators
Market Signals| Indicator | ALL | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 49.19 |
| Support Level | $208.34 | $14.38 |
| Resistance Level | $211.13 | $14.42 |
| Average True Range (ATR) | 3.50 | 0.15 |
| MACD | -1.10 | 0.01 |
| Stochastic Oscillator | 2.06 | 38.99 |
Price Performance
Historical ComparisonAbout ALL Allstate Corporation (The)
Allstate is one of the largest US property-casualty insurers in the US. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 6,000 exclusive agents.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.